Janet Hammond's most recent trade in Atea Pharmaceuticals Inc was a trade of 177,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Jan. 31, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Atea Pharma Inc | Janet Hammond | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2026 | 177,000 | 177,000 | - | - | Stock Option (Right to Buy) | |
| Atea Pharma Inc | Janet Hammond | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2026 | 58,050 | 141,801 | - | - | Common Stock | |
| Atea Pharma Inc | Janet Hammond | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2026 | 46,800 | 0 | - | - | Restricted Stock Units | |
| Atea Pharma Inc | Janet Hammond | Chief Development Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.24 per share. | 31 Jan 2026 | 14,136 | 127,665 | - | 4.2 | 59,937 | Common Stock |
| Atea Pharma Inc | Janet Hammond | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2026 | 11,250 | 0 | - | - | Restricted Stock Units | |
| Atea Pharma Inc | Janet Hammond | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 200,000 | 200,000 | - | - | Stock Option (Right to Buy) | |
| Atea Pharma Inc | Janet Hammond | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2025 | 46,800 | 84,272 | - | - | Common Stock | |
| Atea Pharma Inc | Janet Hammond | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2025 | 46,800 | 46,800 | - | - | Restricted Stock Units | |
| Atea Pharma Inc | Janet Hammond | Chief Development Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.06 per share. | 31 Jan 2025 | 14,134 | 81,388 | - | 3.1 | 43,250 | Common Stock |
| Atea Pharma Inc | Janet Hammond | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 11,250 | 11,250 | - | - | Restricted Stock Units | |
| Atea Pharma Inc | Janet Hammond | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 11,250 | 95,522 | - | - | Common Stock | |
| Atea Pharma Inc | Hammond Janet | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2024 | 225,200 | 225,200 | - | - | Stock Option (Right to Buy) | |
| Atea Pharma Inc | Janet Hammond | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2024 | 46,800 | 93,600 | - | - | Restricted Stock Units | |
| Atea Pharma Inc | Janet Hammond | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2024 | 46,800 | 49,391 | - | - | Common Stock | |
| Atea Pharma Inc | Janet Hammond | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 3.84 per share. | 31 Jan 2024 | 14,029 | 35,362 | - | 3.8 | 53,913 | Common Stock |
| Atea Pharma Inc | Janet Hammond | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2023 | 196,600 | 196,600 | - | - | Stock Option (Right to Buy) | |
| Atea Pharma Inc | Janet Hammond | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2023 | 140,400 | 140,400 | - | - | Restricted Stock Units | |
| Atea Pharma Inc | Janet Hammond | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2022 | 190,000 | 190,000 | - | - | Stock Option (Right to Buy) |